Simvastatin in severe hypercholesterolaemia: a placebo controlled trial

The effect of simvastatin in 27 patients with severe primary hypercholesterolaemia was assessed by a double‐blind placebo controlled parallel group trial. Total serum cholesterol, LDL‐cholesterol and apoprotein B (ApoB) were significantly reduced by simvastatin 40 mg daily. Reductions in triglycerid...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of clinical pharmacology Vol. 31; no. 3; pp. 340 - 343
Main Authors:	McDowell, IF, Smye, M., Trinick, T., Shortt, JA, Archibald, MP, Trimble, ER, Nicholls, DP
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-03-1991 Blackwell Science
Subjects:	Adult Aged Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Apolipoproteins B - blood Biological and medical sciences Blood Pressure - drug effects Blood Viscosity - drug effects Cholesterol - blood Double-Blind Method Female General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl CoA Reductases - metabolism Hypercholesterolemia - drug therapy Leukocytes - enzymology Lipids - blood Liver - enzymology Lovastatin - adverse effects Lovastatin - analogs & derivatives Lovastatin - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Simvastatin Transaminases - metabolism Triglycerides - blood Therapeutic efficiency Human Enzyme inhibitor Controlled therapeutic trial Lipids Metabolic diseases Apolipoproteins Long term Biological monitoring Proteins Chemotherapy Hypercholesterolemia Hydroxymethylglutaryl-CoA reductase Antilipemic agent
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The effect of simvastatin in 27 patients with severe primary hypercholesterolaemia was assessed by a double‐blind placebo controlled parallel group trial. Total serum cholesterol, LDL‐cholesterol and apoprotein B (ApoB) were significantly reduced by simvastatin 40 mg daily. Reductions in triglyceride and VLDL‐cholesterol and an increase in HDL‐cholesterol levels were only significant when calculated as a percentage of baseline, because of wide inter‐individual variability. No changes in apoprotein A1, lipoprotein (a), fibrinogen, viscosity or blood pressure were observed. Leucocyte HMG‐CoA reductase activity was unchanged after 4 weeks of active treatment but increased by 87% after 3 months (n = 21, P less than 0.05). No severe adverse effects or changes in CK or AST levels were noted. We conclude that simvastatin is effective in the treatment of severe and resistant hypercholesterolaemia, and well tolerated in the short term.
ISSN:	0306-5251 1365-2125
DOI:	10.1111/j.1365-2125.1991.tb05539.x